All News

Nationally, the number of drug shortages has tripled since 2005. Our county’s hospice agency has experienced shortages of liquid morphine, scopolamine patches, and medications to relieve nausea. Other generic drug shortages in our clinic have included paclitaxel, leucovorin, and doxorubicin. We have had limited ability to order fluorouracil (5-FU) and mitomycin.

This article addresses some of the most common major challenges in oncologist-patient communication with a nuanced approach to the concepts of autonomy, paternalism, and culture.

The end of another year usually inspires us to interesting if not profound reflections, but in my case I am just trying to remember any rainbows of wisdom that appeared to me during 2011. Those who care for cancer patients cannot help but learn new insights about life and death, and since aphorisms are valuable only if spread, why not share a few?

A study published in the journal Cancer shows that breast cancer survivors can experience problems with specific mental abilities up to several years after treatment.

A team of researchers from the University of Connecticut at Storrs and the National Cancer Institute, analyzing US national health data on more than 4,000 racially diverse adults aged 75 years and older, has concluded that despite “ambiguity of recommendations for this group,” cancer screening rates are high in this population.

The results of a study presented at the San Antonio Breast Cancer Symposium (SABCS) prompted enough controversy to warrant a statement from 3 major medical societies and an expert panel teleconference on December 14, 2011 to discuss the analysis of data presented by the MD Anderson Cancer Center physicians.

This review will examine agents with potential activity in the palliation and treatment of skeletal metastases of prostate cancer, and will weigh the clinical-outcomes evidence for and against their broad use.

The active constituent of green tea extract is EGCG, which accounts for 40% of its total polyphenol content. Regular consumption of green tea may reduce the risk of hypertension and positively affect mood.

In addition to endeavors to develop new therapeutics, we should anticipate and prioritize studies that will address questions regarding the efficacy of combination therapy, timing and sequencing strategies, and the development of predictive markers to individualize and optimize therapy.

We are seeing a new era in drug development with the identification of novel intra- and extracellular targets to which therapies are being directed. Perhaps more exciting is learning how to optimize standard therapies in combination with biologic agents and radiopharmaceuticals in order to target multiple pathways in prostate cancer growth. Stay tuned!

TALK NERDY TO US TAKE OUR TECH SURVEY FOR A CHANCE AT $500! What are physicians saying, thinking - and doing - when it comes to implementing office technologies? Help us to help you find out by completing our easy survey. We are working with our sister site, PhysiciansPractice.com, to learn all about it -- and we're willing to pay. Just go to the 2012 Tech Survey to complete our easy survey, and enter to win a $500 Visa gift card. It only takes five minutes. The contest will run through February 29th. No purchase is necessary. Void where prohibited. See official rules for full details, available here. Thank you for your participation!

The episode-of-care project is the first program in which a payer has partnered with the oncology community to reduce costs while paying for the demanding and complex cognitive work of the medical oncologist. The episode-of-care payment system seems to be working smoothly and we have not experienced the same erosion of our income that we have seen with other payers.

CancerNetwork presents exclusive coverage from the American Society of Hematology (ASH) annual meeting. Check back for an interview with Andrew Evens, DO, MSc, on the oral abstract he's presenting at the meeting called "Lymphoma in Pregnancy: Excellent Fetal Outcomes and Maternal Survival in a Large Multicenter Analysis." Dr. Evens is the deputy director for clinical and translational research and medical director of the Clinical Research Office at the UMass Memorial Health Care Cancer Center of Excellence.

As insurers, clinicians and the U.S. government attempt to slow the increasing rise of health care costs, many experts have identified the tool entitled “clinical pathways” as a solution. Oncologists who adhere to such pathways are thought to improve patient care and reduce expenses.

n their article, Dennis et al call for timely integration of palliative care into standard oncology care and sustained collaboration between these two specialties, to provide comprehensive, individualized care for patients with advanced, incurable cancer and their families.[

Authors von Gunten, Lutz, and Ferris have provided oncologists, and all physicians with patients who have cancer, an excellent and pithy review of how those with very advanced cancer are currently cared for as they approach the end-of-life

This article will review the overlap between palliative care and oncology and discuss the available evidence that true integration of palliative and oncology care provides patients with optimal oncology care.

Patients with advanced progressive cancer require care plans that address their physical, emotional, and psychosocial needs, as well as their goals of care.

In this article, prognostic data are summarized and a suggested approach for discussing hospice enrollment with patients is presented.

CancerNetwork presents exclusive coverage from the annual San Antonio Breast Cancer Symposium. As part of our preconference coverage, we present an interview with Dr. Kent Osborne, director of the Lester and Sue Smith Breast Cancer Center and the Dan L. Duncan Cancer Center at the Baylor College of Medicine, where he is also a professor of medicine in cellular and structural biology. Dr. Osborne is the moderator of the year in review session and he has been involved with the meeting since its beginning.Check back here for news and updates to come.

The article by Aneja, Gross, Soulos, and Yu outlines applications of geographical information systems (GIS) software to oncology research.

Flax, an annual plant believed to have originated in Egypt, is cultivated around internationally and is among the world’s oldest crops.

This review describes the development and technical capabilities of GIS, potential applications of Geographical Informational Systems in cancer research, and the limitations of such work.

This article summarizes some of the most important federal coverage provisions and safeguards that promote access to preventive services for individuals with cancer or individuals who are at risk for cancer

 The goal of this supplement is to present a comprehensive overview of the major current and emerging treatment options for patients with relapsed and/or refractory multiple myeloma.

Oncologist Compensation 2011Is your compensation keeping pace with that of your fellow oncologists? We surveyed practicing oncologists all across the country about their compensation and overall health of their practices. See what they said, then join the conversation about how your practice is different. View results from the 2011 Compensation Survey in our slideshow.

The goal of this supplement is to present a comprehensive overview of the major current and emerging treatment options for patients with relapsed and/or refractory multiple myeloma, with particular focus on proteasome inhibitors and immunomodulatory drugs, along with other emerging agents (eg, histone deacetylase inhibitors, heat shock protein inhibitors, and monoclonal antibodies). As the treatment landscape has evolved, it has become readily apparent that the available therapies have different tolerability profiles depending on patient and disease characteristics.

The Future of Treatment for Patients With Relapsed/Refractory Multiple MyelomaThe supplement and associated publication costs were funded by Onyx Pharmaceuticals

A study has been released that demonstrates the cost-effectiveness of Medicare-funded cancer care treatment programs.

Find out how your compensation, bonuses, and benefits compare to your peers. Data exclusive to CancerNetwork.